Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CK0801 in Treatment-Resistant Guillain-Barré Syndrome
NCT03773328Phase 1Withdrawn
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Regulatory T Cells (Tregs)
01
Overview
Phase 1, open-label trial of CK0801 in Guillain-Barré syndrome (GBS). Primary endpoints: Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0 at 24 hours, Number of Participants with Regimen Related Death at 30 days and 1 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
CK0801
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT03773328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773328.